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East Coast fever (ECF) is a devastating tick-borne disease 
of cattle caused by the protozoan parasite, Theileria parva. 
The disease causes high mortality (greater than 80%) in 
susceptible cattle populations. ECF occurs in 11 countries 
in eastern, southern and central Africa where the tick 
vector, Rhipicephalus appendiculatus, is found. ECF causes 
major economic losses throughout the region and affects 
both high-grade dairy cattle and young zebu cattle in 
smallholder and pastoralist systems and ranches. 
The infection and treatment method (ITM) vaccine was 
developed at Muguga, Kenya, between 1967 and 1977. Since 
then, various versions of the vaccine have been developed, 
each differing in the strains of theilerial parasites used to 
inoculate cattle. The most widely used version is known 
as the ‘Muguga cocktail’, a combination of three parasite 
stabilates. 
The International Livestock Research Institute (ILRI) 
produced the first commercial batch of the Muguga 
cocktail ITM vaccine in the mid-1990s, at the request of the 
Food and Agriculture Organization. A decade later, this time 
at the request of the African Union-Interafrican Bureau for 
Animal Resources, ILRI produced a second batch, which 
is now being used in eastern Africa. A third batch is being 
produced by the Centre for Ticks and Tick-Borne Diseases 
in Malawi, facilitated by GALVmed (the Global Alliance  
for Livestock Veterinary Medicines) and the Bill and 
Melinda Gates Foundation and using tick and parasite seed 
stabilates transferred from ILRI. 
To date, over one million cattle have been immunized with 
the ILRI-produced vaccines. These have been delivered 
by commercial distributors, in particular VetAgro Limited 
who pioneered the commercial feasibility of the vaccine 
in northern Tanzania. The vaccine has been registered in 
Kenya, Malawi and Tanzania, and is approved for use in 
Uganda pending official registration. 
Despite these successes, much needs to be done. Production 
of the live ECF vaccine is complicated, time-consuming and 
expensive. To produce one million doses of vaccine requires 
130 cattle that have not previously been exposed to the 
disease, 500 rabbits and at least 600,000 ticks. The entire 
process of making, testing and releasing a batch takes up 
to 18 months. The product then requires a cold chain and 
careful handling throughout storage, distribution and delivery, 
before being administered by trained veterinary personnel. 
To take stock of the current situation and identify 
improvements in the vaccine, including delivery,  
manufacturing processes and the product itself, ILRI 
and GALVmed recently convened a workshop on the 
‘distribution, delivery and improvement of the Infection and 
Treatment Method vaccine for East Coast fever (ECF)’. 
Participants were drawn from Departments of Veterinary 
Services, regulatory authorities, international development 
organizations, manufacturers, research institutions, and 
private and public partners involved in the delivery of the 
vaccine. It was perhaps the first such meeting of the full 
‘vaccine chain’ for East Coast fever.
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East Coast Fever endemic regionsWorkshop participants came up with priority research 
activities in two areas: improving the production process 
and improving the end-product. 
Research agenda for product and process 
improvements 
In terms of a research agenda, participants identified and 
prioritized the most needed improvement in both the ITM 
product and its manufacturing process. Priority areas to 
work on to improve the product are: 
1. Thermostability. The need for a cold chain is a major 
hindrance in the delivery of the vaccine.  It operates at 
several stages: 
•	 The vaccine – making the vaccine stable at room 
temperature would have enormous benefits, 
although it is considered a long-term, high-risk 
undertaking at present. 
•	 The diluent – it was recognized that a simpler 
diluent would be cheaper and more stable at room 
temperature. Activities are already under way to 
develop such a diluent – a desired stability would be 
six months at room temperature. 
•	 Post-reconstitution stability – the sporozoites 
can be kept at 4°C for up to four hours without 
affecting vaccine performance. The need for 
increased time is less important if a smaller dose   
(5–10) package is available. Improve stabilizers 
to keep stabilate viable from 4 to 12 hours post 
thawing would be highly beneficial. 
2. Removal of oxytetracycline (OTC).The need for OTC 
adds considerably to the cost of the vaccine. Extra 
labour is also required as the dose of tetracycline 
depends on the weight of the animal. In addition, 
the approval of different brands of OTC requires in 
vivo testing. It was suggested that research should 
be undertaken to explore ways of attenuating the 
parasite to make it self-limiting. One approach is by 
irradiation, as has been used in closely-related malaria 
organisms. 
3. Different dose presentations. The current straw 
contains 40 doses, which is not suitable for smallholder 
areas where a presentation of 5 – 10 doses is desirable. 
The smaller dose straw would cost more on a per dose 
basis, although this would be offset by the reduction in 
wastage and the fact that the target animals are high 
value ones. Data on cost versus convenience is needed. 
Sensitization of farmers on the change in packaging is 
essential to avoid suspicion. 
4. Buffalo challenge. Evidence is available indicating that 
the Muguga cocktail does not fully protect cattle that 
share pastures with buffalo; other reports indicate that 
the vaccine is effective against buffalo-derived challenge. 
Lack of protection limits the wider use of the vaccine 
and poses a reputational risk. It was requested that 
more epidemiological research be undertaken on the 
importance of buffalo (i.e. how many cattle are exposed 
to the buffalo-derived parasites) and how can the 
vaccine be changed to protect against the challenge of 
buffalo-derived parasites. 
5. Long term impact of mass immunization on 
epidemiology of the disease. Vaccination with ITM can 
induce a carrier state in immunized animals, which 
allows the parasites in the vaccine stabilate to be 
transmitted to other animals.The effect of this on the 
existing parasite population is not known. 
6. One vaccine for all regions. A single vaccine stabilate 
that could be applied in all regions where ECF exists 
would provide efficiencies of scale in the manufacturing 
and distribution of the vaccine. However, due to 
the existence of strain variation among the T. parva 
parasites, there are concerns whether broad immunity 
in the field can be induced by a vaccine composed of a 
single stabilate. 
In terms of the vaccine manufacturing process, 
improvements that require research inputs are: 
1. Decreasing the number of animals used in the 
production process. The current procedure requires a 
large number of animals both to produce the vaccine 
and for the pre-release testing. One alternative to 
using animals in the production process is to use an 
in vitro culture of the parasite. This is considered very 
challenging from a technical perspective and not for 
immediate application. In terms of testing, the current 
protocol requires three rounds of testing for each 
vaccine batch, plus an initial infectivity trial. This should 
be re-examined to see if it can be reduced. It was noted 
that work is ongoing to establish an in vitro correlate 
of infectivity, which could be used to assess the potency 
of each batch and reduce the amount of in vivo testing 
required. 
2. Decreasing time for production. Concern was 
expressed about the current time required to produce 
a batch of the vaccine (up to 18 months), particularly 
with the expected increase in demand of the vaccine. 
The most immediate way to reduce the time is to 
decrease the number of rounds required for dose 
determination. The use of staggered production cycles 
should also be considered. 
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A next generation vaccine 
Research at ILRI and elsewhere has demonstrated that there are two major entry points for development of a subunit vaccine for the 
control of ECF. The first is through generation of antibodies that have the capacity to neutralize sporozoites, the infective life-cycle stage 
of T. parva. The second is through priming of cytotoxic T cells that kill schizont-infected lymphocytes, the pathogenic stage of T. parva. 
Candidate T. parva vaccine antigens have been identified and under laboratory conditions they induce immunity to ECF in 30-50% of  
vaccinated cattle. 
In January 2014, an inception workshop was held at ILRI to bring together leading experts in ECF and infectious disease research from 
more than eight institutions to work together to obtain proof-of-concept for a subunit vaccine for ECF. Over the next 5-10 years, this 
ECF Consortium will harness new science and undertake various research activities to fill current knowledge gaps. Its primary objec-
tive is to demonstrate immunity to ECF in 70-80% of a defined type of cattle given a defined parasite challenge, with a second phase to 
provide broad-spectrum immunity. In the interim, the ITM vaccine is the only vaccine solution available for the control of ECF and various 
research activities are being undertaken to improve the manufacture and delivery of this live, parasite-based vaccine. 
More: http://ilvac.net/diseases/ecf/ 
3.  Increasing batch sizes. It was noted that increasing the 
number of sporozoites produced in each manufacturing 
run would help to meet the expected increase in demand. 
Potential ways to achieve this include looking at alternative 
tick strains to increase sporozoite yields, improving 
grinding methods to increase recovery of sporozoites 
from ticks and improving the freezing process to allow for 
better sporozoite viability rates on thawing. 
4.  Improving diluent containers. Suggestions to improve 
the diluent container included: changing from a glass 
container to a plastic one, using a unique cap colour for 
each batch, and ensuring that the size of the container 
is suitable for the amount of diluent required for each 
batch of straws (which is related to the number of 
doses per straw). 
Other topics for research included identifying ticks which 
can yield greater number of sporozoites, and  validating the 
use of other antibiotic formulations 
Agenda for vaccine delivery and uptake 
•	 Availability	–	there	needs	to	be	a	reliable	vaccine	supply	
chain able to produce enough vaccine to meet demands 
•	 Awareness	-	there	needs	to	be	a	campaign	to	sensitize	
stakeholders 
•	 Vaccinators	have	key	roles	at	the	front	line	–	these	
need to be reinforced through training and certification 
•	 Having	standard	operating	procedures	is	essential	to	
ensure good quality vaccine delivery and uptake 
•	 Practical	elements	of	the	straw	size	are	a	critical	issue	
in packaging of the vaccine 
•	 Smart	partnerships,	where	different	actors	can	meet	
on a regular basis is very critical to fostering good 
communications and trust. 
Priority actions 
Workshop participants concluded that: 
1. An emerging, demand-driven research agenda for the 
ITM vaccine must be tackled. 
2.  Although the ITM vaccine manufacturing process is 
complex, the production process can be improved 
(in the short term) resulting in quicker and cheaper 
manufacturing processes. 
3.  A next generation vaccine is under active research but 
has about a 10 year horizon, emphasizing the need to 
continue to improve the ITM vaccine and production 
technology, and to acquire further knowledge on the 
socio-economic impact of the vaccine and its effect on 
the epidemiology of the disease. 
4.  Filling the vaccine supply gap in the short term is a 
critical issue to address. 
5.  A clear timetable for the vaccine availability to 
distributors is urgently needed. Information is also 
needed on any planned controlled release or field-
testing of future batches. 
6.  The registration process in the various countries is key 
to ensuring wide availability of the vaccine and requires 
appropriate actions now. 
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7.  The allocation of vaccine to countries and distributors 
must reflect a fair market distribution governed by 
transparent and reliable processes. 
8.  Improvement is desired in the way that liquid nitrogen 
is handled in the field at all stages of the delivery 
chain, in the thermo-stability of the diluent (preferably 
stable at room temperature) and in the current dose 
presentations, which are not optimal. 
9.  Standard operating procedures for vaccine delivery 
need to be established, based on best practices derived 
from field experience. 
10. Centralized and uniform training and certification of 
vaccinators is essential to ensure that the vaccine is 
delivered safely and effectively. 
11. The roles of the Local Technical Representatives 
(LTR) as well as those of in-country distributors and 
importers need to be finalised. 
12.  A joint ECF communication process is needed to 
catalyze and support sharing and awareness and 
exchange of already existing materials and other 
information across countries.
